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Summary
Hematopoietic stem cells (HSCs) sustain long-term reconstitution of hematopoiesis in 
transplantation recipients, yet their role in the endogenous steady-state hematopoiesis remains 
unclear. In particular, recent studies suggested that HSCs provide a relatively minor contribution to 
immune cell development in the adults. We directed transgene expression in a fraction of HSCs 
that maintained reconstituting activity during serial transplantations. Inducible genetic labeling 
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showed that transgene-expressing HSCs gave rise to other phenotypic HSCs, confirming their top 
position in the differentiation hierarchy. The labeled HSCs rapidly contributed to committed 
progenitors of all lineages and to mature myeloid cells and lymphocytes, but not to B-1a cells or 
tissue macrophages. Importantly, labeled HSCs gave rise to more than two-thirds of all myeloid 
cells and platelets in adult mice, and this contribution could be accelerated by an induced 
interferon response. Thus, classically defined HSCs maintain immune cell development in the 
steady state and during systemic cytokine responses.
eTOC/In Brief
The role of hematopoietic stem cells (HSCs) in steady-state hematopoiesis remains controversial. 
Here, Sawai et al. use lineage tracing to reveal a major contribution of HSCs to all blood cell 
lineages, including myeloid cells and lymphocytes, throughout the adult life.
Introduction
Throughout the adult life, all blood cell types including platelets, erythrocytes and 
leukocytes undergo constant replenishment from the bone marrow (BM). Continuous blood 
development (hematopoiesis) is particularly important for the immune system, in which 
myeloid cells such as granulocytes, monocytes and dendritic cells (DCs) are very short-lived 
(Geering et al., 2013; Geissmann et al., 2010). Peripheral T and B lymphocytes are relatively 
long-lived and may be sustained in part by homeostatic proliferation, yet they require the 
input of new cells to maintain a diverse polyclonal repertoire of antigen specificities 
(Montecino-Rodriguez et al., 2013). The only exceptions are cell types that develop 
primarily during embryogenesis, such as tissue macrophages (MΦ) (Ginhoux and Jung, 
2014) and innate-like lymphocytes such as B-1a cells (Montecino-Rodriguez and Dorshkind, 
2012). Dysregulation of hematopoiesis is associated with immunodeficiencies and age-
related immune dysfunction, and is a direct cause of myelodysplastic syndromes and 
leukemia.
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The BM of adult mammals maintains a rare population of hematopoietic stem cells (HSCs) 
that can permanently reconstitute blood formation when transferred into lethally irradiated 
or otherwise myelosuppressed hosts (Eaves, 2015; Shizuru et al., 2005). The long-term 
reconstituting HSCs are thought to give rise to phenotypically and transcriptionally distinct 
short-term HSCs (ST-HSCs) that lack durable self-renewal and can produce only a transient 
wave of reconstitution. ST-HSCs and the partially overlapping multipotent progenitors 
(MPPs) progressively generate lineage-restricted progenitors and mature cells of the myeloid 
(e.g. granulocytes and monocytes), lymphoid (T, B and NK cells) and megaerythroid 
(platelets and erythrocytes) lineages (Wilson et al., 2015). Transplantation-competent HSCs 
are less proliferative than downstream progenitors (Cheshier et al., 1999; Passegue et al., 
2005; Wilson et al., 2008), and are localized in specific BM microenvironment(s) termed the 
HSC niche (Boulais and Frenette, 2015). The durable reconstitution by HSCs underlies the 
success of clinical hematopoietic transplantation and gene therapy protocols, the life-saving 
therapies for many diseases including leukemia and primary immunodeficiencies.
It has long been assumed that the paradigm of hierarchical HSC differentiation, which was 
derived from transplantation studies, also applies to steady-state hematopoiesis. In other 
words, all hematopoietic cells, including all major immune cell types such as myeloid cells 
and lymphocytes, are continuously generated from endogenous HSCs in the BM. This 
notion, however, has been challenged by recent studies. Thus, clonal cell analysis using 
transposon-mediated “barcoding” suggested that granulocyte development is completely 
uncoupled from the HSC activity (Sun et al., 2014). A subsequent study using lineage 
tracing showed that genetically labeled HSCs did contribute to myeloid and lymphoid cells. 
However, the contribution was infrequent, and it was therefore proposed that most mature 
cells are derived primarily from ST-HSCs (Busch et al., 2015). Collectively these studies 
raise the possibility that steady-state hematopoiesis is sustained primarily by progenitors 
rather than by HSCs, with the latter predominantly activated only during hematopoietic 
stress such as transplantation. This model therefore poses a fundamental question in 
developmental immunology, namely: what is the ultimate source of continuous 
lymphopoiesis and myelopoiesis in adult mammals?
The HSC activity in the BM of normal adult mice is contained in a small subset of Lineage 
marker (Lin)− Sca-1+ c-Kit+ (LSK) cells (Ikuta and Weissman, 1992; Morrison and 
Weissman, 1994) that express high levels of CD150 (Slamf1) and endothelial protein C 
receptor (EPCR) but low levels of CD135 (Flt3), CD48 (Slamf2) and CD34 (Balazs et al., 
2006; Forsberg et al., 2005; Kent et al., 2009; Kiel et al., 2005). However, these 
phenotypically defined HSCs are heterogeneous in their differentiation potential and self-
renewal capacity, as revealed by single-cell transplantation (Benz et al., 2012; Challen et al., 
2010; Dykstra et al., 2007; Morita et al., 2010) and genetic reporters (Chen et al., 2016; 
Sanjuan-Pla et al., 2013). Importantly, only a minor fraction of HSCs can support long-term 
multilineage reconstitution in serial transplantations, as opposed to primary transplantations 
(Oguro et al., 2013; Yamamoto et al., 2013). These cells presumably comprise the top of 
hematopoietic hierarchy, yet their contribution to hematopoiesis has not been studied. 
Indeed, genetic labeling in (Sun et al., 2014) was not HSC-specific, and in (Busch et al., 
2015) involved a small (~1%) random fraction of the HSC population. Therefore, an 
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efficient genetic labeling of HSCs, particularly of the most potent HSCs with superior self-
renewal capacity, is required to elucidate their contribution to endogenous hematopoiesis.
Here we developed genetic systems to prospectively label HSCs with serial reconstitution 
capacity, and to test their fundamental properties in unperturbed animals. The labeled HSCs 
gave rise to other cells within the HSC population, confirming their highest position in the 
hematopoietic hierarchy. Importantly, these HSCs provided a major sustained contribution to 
hematopoiesis in the steady state and during interferon response. Our results therefore favor 
a view in which HSCs provide an ultimate source of adult immune cell development.
Results
Pdzk1ip1-GFP transgene is expressed in a subset of HSCs
To genetically mark and trace HSCs, we used bacterial artificial chromosome (BAC) clones 
to drive transgene expression from the Pdzk1ip1 locus. Pdzk1ip1 (also known as Map17) is 
expressed in the murine HSC population but is strongly reduced in more differentiated cells 
or in mobilized HSCs (Cabezas-Wallscheid et al., 2014; Forsberg et al., 2010; Wilson et al., 
2015). We used a BAC clone containing the entire Tal1-Pdzk1ip1 locus to direct the 
expression of green fluorescent protein (GFP) from the Pdzk1ip1 gene (Fig. S1A). The 
resulting GFP transgene was expressed at high levels in all LSK CD150+ CD48− HSCs; 
however, it was also detectable in some LSK CD150− CD48+ multipotent progenitors 
(MPPs), and the majority of Lin− Sca1− c-Kit+ CD150+ megakaryocyte-erythrocyte 
progenitors (MEPs) (Fig. S1B–D).
To improve the specificity of Pdzk1ip1 transgene expression, we dissociated Pdzk1ip1 and 
Tal1 loci by using a 5′ truncated BAC clone lacking the promoter and upstream region of 
Tal1 (Fig. S1A). The resulting Pdzk1ip1-GFP transgene was expressed in a small population 
of Lin− cells, most of which had the HSC phenotype (Fig. 1A). Conversely, the HSC 
population contained ~27% GFP+ cells, whereas progenitors including MPPs, MEPs and 
myeloid progenitors (Lin− Sca1− c-Kit+ CD150−, MyPs) contained <1% of GFP+ cells (Fig. 
1B,C). Some Lin+ cells with lower GFP levels were also detected and found to represent 
mature granulocytes (3–4% of these) (Fig. 1A–C). By several phenotypic definitions 
currently used in the field (Fig. S1E), GFP-expressing cells were enriched among the HSCs 
that were rigorously defined as CD34−/lo (Wilson et al., 2008) or CD229− (HSC-1; Oguro et 
al., 2013) (Fig. 1D,E). Conversely, GFP+ cells expressed lower levels of CD34 and CD229 
and higher levels of EPCR than the GFP− cells (Fig 1F). Finally, we tested the proliferation 
of HSC populations by measuring the incorporation of nucleoside analogue 5-
bromodeoxyuridine (BrdU) in vivo. As shown in Fig. 1G, GFP+ HSCs showed the lowest 
rate of BrdU incorporation compared to GFP− HSCs or progenitors. Thus, the 5′ truncated 
Pdzk1ip1 transgene was preferentially expressed in a subset of HSCs with the most 
undifferentiated phenotype and the lowest proliferation rate.
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Transgene-expressing HSCs have an undifferentiated expression profile and serial 
reconstitution capacity
We performed global mRNA sequencing (RNA-Seq) of sorted GFP+ and GFP− HSCs, along 
with the MPP population from the same pooled sample as a control. Clustering and principal 
component analysis (PCA) of the resulting expression profiles confirmed the expected 
differences between HSCs and MPPs, and the high concordance between GFP+ and GFP− 
HSCs (Fig. 2A and Dataset S1). The expression of Pdzk1ip1 was only slightly enriched in 
GFP+ HSCs, confirming that the truncated Pdzk1ip1-GFP transgene has a more restricted 
expression than the endogenous gene. Consistent with their immature phenotype, GFP+ 
HSCs showed a slight decrease of differentiation markers (e.g. Cd34, Itga2b and Cd48) and 
of multiple genes associated with proliferation (e.g. Mki67, Ccne2). (Dataset S1). Direct 
comparison with RNA-Seq profiles of wild-type HSCs and progenitor populations (Cabezas-
Wallscheid et al., 2014) showed that genes enriched in GFP+ compared to GFP− HSCs were 
also highly enriched in wild-type HSCs compared to their immediate progeny (MPP1), and 
vice versa (Fig. 2B). Furthermore, combined PCA of all samples showed that GFP+ HSCs 
segregated closest to the HSC samples of (Cabezas-Wallscheid et al., 2014) (data not 
shown). We conclude that the expression profile of GFP+ HSCs is consistent with the least 
differentiated status, including the reduction of differentiation markers and proliferation 
signature genes.
We tested the reconstitution capacity of Pdzk1ip1 transgene-expressing HSCs in serial 
transplantations. Primary transplantation of GFP+ or GFP− HSCs yielded comparably robust 
and lineage-balanced reconstitution of myeloid (granulocytes, monocytes), lymphoid (T and 
B cells) and megakaryocytic (platelets) lineages when HSCs were isolated as LSK CD48− 
CD150+ (Fig S2A) or as LSK CD135− cells (Fig S2B). Notably, GFP+ HSCs regenerated 
both GFP+ and GFP− HSCs in transplanted hosts, whereas recipients of GFP− HSCs 
contained only GFP− cells (Fig. 2C). Thus, GFP+ HSCs could give rise to GFP− HSCs but 
not vice versa. Moreover, GFP− HSCs generated from the original GFP+ cells in primary 
recipients showed poor reconstitution of secondary recipients, in contrast to the robust 
activity of the HSCs that retained GFP expression (Fig S2C).
We then transplanted recipient mice with 20 GFP+ or GFP− HSCs defined as CD45+ EPCR+ 
CD48− CD150+ (ESLAM) (Kent et al., 2009) (Fig. 2D). Both subsets gave robust 
reconstitution of all primary recipients at 8–12 weeks (data not shown) and at 16 weeks (Fig. 
2E). However, again only the GFP+ progeny of these GFP+ ESLAM HSCs reconstituted 
secondary recipients (Fig. 2E). Of note, the majority of GFP+ ESLAM HSCs recipients 
showed multilineage reconstitution of granulocytes, T and B cells (6/6 and 6/8 in primary 
and secondary transplantations, respectively). In single-cell transplantations, 5 out of 14 
primary recipients showed multilineage reconstitution (Fig. S2D), whereas 8/14 primarily 
reconstituted granulocytes (corresponding to α- and β-HSCs, respectively (Dykstra et al., 
2007)). Thus, the Pdzk1ip1 transgene expression selectively marks HSCs that are uniquely 
capable of reconstituting secondary recipients. Collectively, the transgene-expressing HSCs 
display the most undifferentiated phenotype and expression profile, serial multilineage 
reconstitution capacity and the ability to regenerate themselves and the transgene-negative 
subset.
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Pdzk1ip1-CreER transgene specifically labels undifferentiated HSCs
To inducibly label and trace the Pdzk1ip1 transgene-expressing HSCs, we created mice 
expressing a tamoxifen-inducible Cre recombinase-estrogen receptor fusion protein (CreER) 
under the control of the same 5′ truncated Pdzk1ip1 BAC clone. The resulting Pdzk1ip1-
CreER transgenic animals were crossed to the Rosa26tdTomato (R26Tom) strain, in which Cre 
recombination permanently activates expression of the red fluorescent protein tdTomato 
(Tom). Three days after a single administration of tamoxifen, Tom expression was observed 
in a small fraction of BM cells, the majority of which represented HSC (Fig. 3A). The 
labeling was observed in a fraction of HSCs (mean, 32.6%; median 30%, Fig. 3B,C) that 
was comparable to the Pdzk1ip1-GFP mice. The labeling was selective for HSCs, as it was 
observed in only ~3% of MPPs and <0.6% of all downstream progenitors (Fig. 3B,C). In 
addition to HSCs, the expression of Pdzk1ip1 transgenes was detected in the kidney, 
reproductive system, and skin (data not shown). Unlike in the Pdzk1ip1-GFP transgene, no 
“leaky” labeling of granulocytes was observed, likely because of lower transgene expression 
levels in these cells.
As in the case of Pdzk1ip1-GFP+ cells, the labeled Tom+ cells were significantly enriched 
among the CD34−/lo HSCs (Wilson et al., 2008) (Fig. 3D). No significant difference was 
observed between CD229− HSC-1 and CD229+ HSC-2 (Oguro et al., 2013), yet both 
phenotypes were highly enriched for Tom+ cells compared to ST-HSCs or progenitors (Fig. 
3E). Moreover, Tom+ HSCs had slightly lower CD34 and CD229 and higher EPCR levels 
than the Tom− cells (Fig. 3F). To directly compare the HSC subsets labeled by GFP and 
CreER transgenes, we crossed the two transgenic strains and analyzed GFP and Tom 
expression 3 days after tamoxifen treatment. Despite a lower GFP expression in double-
transgenic compared to single-transgenic mice, the fraction of GFP+ HSCs was significantly 
enriched in the Tom+ population, and vice versa (Fig. S3A–C). Thus, similar to the 
Pdzk1ip1-GFP transgene, Pdzk1ip1-CreER preferentially labels a subset of HSCs with the 
most immature phenotype.
HSCs are thought to turn over slowly and therefore to retain labeled DNA or chromatin 
(Foudi et al., 2009; Wilson et al., 2008). To analyze label retention, the Pdzk1ip1-CreER 
mice were crossed with the mice that allow global doxycycline (Dox)-inducible expression 
of the histone 2B-GFP (H2B-GFP) fusion protein (Foudi et al., 2009). The resulting 
Pdzk1ip1-CreER R26Tom R26rtTA Col1a1tetO-H2BGFP mice were administered Dox for 6 
weeks to induce H2B-GFP and then kept without Dox for 14 weeks to allow label dilution. 
The mice were then induced with tamoxifen and analyzed 3 days later for the expression of 
GFP in the labeled Tom+ HSC subset. Up to 50% of Tom+ HSCs retained H2B-GFP, 
whereas the H2B-GFP+ fraction was significantly lower in Tom− HSCs and virtually absent 
in progenitors (Fig. 3G). These data suggest that the labeled HSCs are heterogeneous with 
respect to label retention but are enriched in label-retaining cells. The intensity of H2B-GFP 
signal in Tom+ HSCs was progressively decreasing with time (data not shown), suggesting 
that they still undergo substantial proliferation.
The labeled Tom+ HSCs could be detected in frozen BM sections by their native red 
fluorescent signal, and were confirmed to express CD150 but not lineage markers, CD48 or 
CD41 (Fig. S3D,E). Simultaneous staining for endothelium showed that most Tom+ HSCs 
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were located adjacent to the endomucin-positive endothelium of the sinusoids (Fig. 3H), 
consistent with recent observations (Acar et al., 2015; Ding and Morrison, 2013). Given the 
broad distribution of sinusoids in the BM (Kunisaki et al., 2013), the identity of cell types 
and vessels adjacent to Tom+ HSCs still remains to be determined. Overall, the labeled 
HSCs demonstrate preferential label retention and perivascular localization, the expected 
attributes of a bona fide HSC.
Labeled HSCs give rise to other phenotypic HSCs
We used lineage tracing to analyze the progeny of labeled HSCs. If labeled cells represent a 
random sampling of the HSC population, their frequency would remain constant over time, 
as observed previously (Busch et al., 2015). On the other hand, if labeled HSCs give rise to 
other cells within the HSC population, the fraction of labeled HSCs would increase with 
time. Indeed, the initial fraction of labeled HSCs increased ~2-fold after several weeks (Fig. 
4A). Serial BM biopsies of the same tamoxifen-induced animals confirmed the rapid 
increase in labeled HSCs by 12 weeks, eventually reaching 80–90% Tom+ by 46 weeks (Fig. 
4B). As expected, the labeling of immediate HSC progeny (ST-HSCs and MPPs, Fig. S4A) 
increased >5-fold by 11–12 weeks, and approached (but did not equal) that of HSCs by 28–
40 weeks (Fig. 4A,B). The fluorescence intensity of Tom in HSCs increased as well, likely 
reflecting its accrual in these slowly dividing cells (Fig. S4B). Thus, similar to 
transplantation settings, the labeled HSCs give rise to other cells within the HSC population, 
suggesting that they represent the highest level of hematopoietic hierarchy. Furthermore, the 
actual initial labeling of this “top-level” HSC subset must have been high (80–90%) to allow 
the similarly high endpoint labeling of the entire HSC compartment (Fig. 4C).
Labeled HSCs contribute to all hematopoietic lineages
We analyzed the spectrum of top-HSC differentiation into hematopoietic progenitors 
(defined as in Fig. S5A,B). Because minor fractions of ST-HSCs and MPPs were labeled at 
the outset of lineage tracing (>10%, Fig. 4A,B), the origin of Tom+ cells below these 
frequencies cannot be ascertained in our tracing experiments. However, any Tom+ cells 
above these frequencies must necessarily have arisen from an upstream population with the 
highest labeling, i.e. the HSCs. We found that the labeling of lineage-restricted erythroid 
(EryPs), megakaryocytic (MkPs), myeloid (MyPs), and monocyte and dendritic cell (MDPs, 
CDPs) progenitors reached >30% 11 weeks post-induction (Fig. 5A). Common lymphoid 
progenitors (CLPs), early thymic T cell progenitors (ETPs) and immature thymocytes 
showed lower labeling at 4–11 weeks, consistent with the slower kinetics of HSC 
differentiation into lymphoid progenitors as observed before (Busch et al., 2015). However, 
by 36 weeks the labeling of all progenitors reached or exceeded ~60%, revealing a major 
contribution of labeled HSCs to all lineages.
We used serial BM biopsy to examine the differentiation of labeled HSCs into mature 
granulocytes (Gr), asking in particular how very few HSCs could sustain the massive 
continuous production of these cells. The biopsy itself did not affect the rate of HSC 
differentiation as judged by the emergence of labeled Gr (Fig. S5C). The labeling of 
common progenitors (MPPs), committed progenitors (MyPs) and the terminal differentiated 
progeny (Gr) followed a nearly identical kinetics from <3% at the outset to ~70% by 46 
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weeks (Fig. 5C). These data suggest that the rate-limiting HSC-to-MPP transition is 
followed by the rapid and linear differentiation of MPPs to granulocytes. Fig. 5D shows a 
mathematical model of this process with estimated values of differentiation and regeneration 
for each cell population. For the labeled HSCs at the top of the differentiation sequence, 
these rates are equal as expected for a fully self-renewing compartment. For the downstream 
compartments, these rates appear very close, i.e. all inputs are amplified and converted into 
the output. Notably, the absolute values of these rates progressively increase by several 
orders of magnitude, reflecting the increasing proliferation rates and cell numbers in each 
progenitor population. Thus, the few differentiating HSCs can continuously produce large 
numbers of granulocytes through massive amplification at progenitor stages.
The kinetics and spectrum of HSC differentiation into peripheral cells
We examined tamoxifen-induced Pdzk1ip1-CreER R26Tom mice by peripheral blood (PB) 
sampling (Fig. S6A). The procedure itself did not affect the rate of HSC differentiation 
compared to the endpoint analysis (Fig. S5C). Labeled platelets and myeloid cells became 
detectable at 2 and 4 wks, respectively, and thereafter increased in parallel to reach ~66% by 
32 wks (Fig. 6A). Peripheral NK, T and B cells were labeled with a longer lag period (8–12 
weeks) and respectively lower rates (Fig. 6A). Endpoint analysis confirmed that myeloid 
cells including granulocytes, monocytes and DCs (Fig. S6B) became labeled up to 60–70% 
at 36–46 wks (Fig. 6B). Similarly, high labeling frequencies were observed in NK cells, 
thymocytes and immature B cells in the BM, confirming that the slow labeling of peripheral 
lymphocytes reflects their slow turnover (Fig. 6B). The endpoint labeling of mature cells 
(60–70%) approached that of HSCs (80–90%) but did not fully equilibrate with it (Fig. 6B), 
suggesting that a few HSCs did not differentiate within the analyzed period.
We analyzed the cell types that are thought to emerge during embryonic hematopoiesis (Fig. 
S6C). Very few Tom+ cells (<5%) were detected at 36–46 wks among B-1a cells in the 
peritoneal cavity (PC), compared to conventional B cells in the spleen or PC (Fig. 6C). 
Similarly, hardly any labeling was detected in the MΦ in the lung and the brain (microglia) 
or in the resident DCs in the epidermis (Langerhans cells) (Fig. 6D). A higher fraction of 
Tom+ cells (20–30%) was found among MΦ in the PC, spleen and liver (Kupffer cells) (Fig. 
6D). Thus, the contribution of HSCs to embryo-derived immune cell types is limited but 
varies substantially between tissues.
We treated tamoxifen-induced mice with the double-stranded RNA polymer poly-I:C, an 
inducer of type I interferon that increases HSC proliferation (Essers et al., 2009; Pietras et 
al., 2014). We found that the pattern of HSC contribution to peripheral cells was similar to 
that in the steady state (Fig. 7A). However, the kinetics was greatly accelerated, so that the 
same ~70% labeling of myeloid cells and platelets was reached in only half the time (Fig. 
7A). Moreover, at the 40 wk endpoint the fraction of Tom+ progenitors and mature cells 
(~90%, Fig. 7B) approached that of Tom+ HSCs (~95%, shown in the figure as a dashed 
line). These results suggest that poly-I:C mobilized nearly all labeled HSCs into 
differentiation. The contribution to B-1a cells, Langerhans cells and microglia remained very 
low (<10%, Fig. 7C,D), but increased in MΦ in the spleen (~50%), PC and liver (30–40%). 
Collectively, these results show that HSCs provide a major sustained contribution to steady-
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state hematopoiesis, except for the few embryo-derived immune cell types. This contribution 
could be accelerated by an acute inflammatory stimulus, revealing a feedback control of 
HSC differentiation by innate immune responses.
Discussion
We used the murine Pdzk1ip1 gene as a driver to target the expression of transgenes to the 
HSC population. Though the function of Pdzk1ip1 is not well studied, the gene, unlike in 
mice, is not expressed in human HSCs (Bagger et al., 2016), and consequently it is unlikely 
to have a major role in HSC function. Indeed, the lack of an HSC-intrinsic function is 
characteristic of multiple phenotypic (CD150, EPCR) and genetic (α-catulin) HSC markers. 
The full-length BAC clone recapitulated the expression of endogenous Pdzk1ip1 and 
targeted transgene expression to all HSCs and to some progenitors, similar to several other 
HSC-specific genes (Gazit et al., 2014; Kataoka et al., 2011). In contrast, the artificially 5′ 
truncated Pdzk1ip1 locus targeted transgene expression to a subset of HSC, with only 
minimal expression in progenitors. The artificial 5′ truncation removed the shared 
regulatory regions of Tal1 and Pdzk1ip1, apparently reducing the transgene’s epigenetic 
stability. Indeed, the ectopic expression in a fraction of granulocytes was observed in several 
founder lines of the truncated transgene, but not with the full-length transgene. On the other 
hand, the truncation also likely accounted for the transgene’s unique specificity for 
immature HSCs and the sensitivity to the loss of self-renewal potential.
Whereas the original definition of long-term HSCs reflected their capacity to reconstitute 
primary recipients (Morrison and Weissman, 1994; Spangrude et al., 1988), only a fraction 
of those HSCs were capable of reconstituting secondary recipients (Oguro et al., 2013; 
Yamamoto et al., 2013). Several genetic markers were recently developed to identify HSC 
subsets with a particular lineage bias (Vwf, (Sanjuan-Pla et al., 2013)) or a superior 
reconstitution capacity (Hoxb5, (Chen et al., 2016)) during primary transplantations. 
However, the Pdzk1ip1-based transgene appears distinct in identifying HSCs that excel in 
secondary transplantations. Accordingly, previously used genetic markers showed only 
slight (Hoxb5) or no (Vwf) enrichment in Pdzk1ip1-GFP+ HSCs (Dataset S1). Transgene-
expressing HSCs exhibited the most undifferentiated surface phenotype, relatively slow 
proliferation (as measured by label dilution) and localization in the perivascular niche in the 
BM. Transplanted transgene-expressing HSCs regenerated both themselves and the 
transgene-negative HSCs, whereas by lineage tracing the transgene-expressing HSCs give 
rise to other HSCs in the steady state. Collectively, these data suggest that our system 
identifies the least differentiated subset of HSCs with the highest self-renewal capacity and 
ability to produce other phenotypic HSCs.
The analysis of HSC differentiation by lineage tracing revealed their major sustained input 
to all major hematopoietic lineages. Indeed, HSCs produced the majority of conventional 
myeloid cells and platelets within ~8 months, i.e. less than half of the lifespan of a 
laboratory mouse. Of note, the labeling of progenitors and mature cells (60–70%) did not 
fully equilibrate with that of HSCs (>80%), suggesting that some HSCs do not differentiate 
within this time frame. However, this lack of contribution applies to a minor fraction of 
labeled HSCs, and therefore likely represents reversible quiescence (Wilson et al., 2008) 
Sawai et al. Page 9
Immunity. Author manuscript; available in PMC 2017 September 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
rather than the primary HSC state. Our mathematical model estimates that 3–8% of labeled 
HSCs entered differentiation per day, followed by massive flux amplification at the 
downstream stages. This agrees with a relatively low but nevertheless considerable 
proliferation of all HSCs in the steady state (Cheshier et al., 1999; Kiel et al., 2007; 
Passegue et al., 2005; Wilson et al., 2008) and with the substantial label dilution observed in 
our experiments. The relatively slow but constant HSC input appears to be amplified through 
massive proliferation of progenitors, thereby maintaining continuous development of 
immune cells such as granulocytes.
The observed robust contribution of HSCs to steady-state hematopoiesis contrasts with the 
near-absent contribution of HSCs to granulopoiesis reported by (Sun et al., 2014). This study 
used an ingenious clonal labeling by inducible transposon mobilization, albeit without any 
cell type specificity. More importantly, potential caveats of this approach include secondary 
transpositions (e.g. due to the “leaky” transposase expression after the initial induction), 
and/or false positive integration sites due to multiple rounds of PCR cloning. These 
possibilities were not ruled out, and may have contributed to the observed “uncoupling” of 
barcodes between HSCs and granulocytes. A subsequent steady-state lineage tracing of 
HSCs estimated that ~30% of HSCs contribute to differentiated cells (Busch et al., 2015). 
This study used a CreER strain that labeled only 0.5–1% of the total HSC population 1–3 
weeks after a 5-day tamoxifen treatment. Because of the low labeling efficiency, no 
continuous sampling was used, and the mature cell labeling was estimated relatively to the 
average HSC labeling. Moreover, the low efficiency likely reduced the probability of 
observable HSC differentiation, whereas the long lag before the start of tracing may have 
selected for the most quiescent HSCs. In contrast, our system efficiently labeled a distinct 
subset of “top-level” HSCs (rather than a small random HSC sample) within days after a 
single tamoxifen treatment. This efficient labeling i) facilitated lineage tracing of the 
majority of HSCs with precise timing and continuous sampling; ii) allowed the definition of 
lineage labeling in absolute terms, rather than relative to the fraction of labeled HSCs; iii) 
minimized the adverse effects of tamoxifen on HSCs (Nakada et al., 2014; Sanchez-Aguilera 
et al., 2014). The resulting data are generally consistent with those by Busch et al., but 
suggest a much higher and faster contribution of HSCs to adult hematopoiesis.
With respect to the immune system, two aspects of HSC differentiation appear notable. The 
first is the absent or limited HSC contribution to several immune cell types such as B-1a 
cells and tissue MΦ. These results not only confirmed the primary embryonic origin of these 
cells, but also revealed a marked variability in their maintenance. Thus, microglia and 
Langerhans cells received virtually no HSC input, consistent with their proposed earliest 
derivation in the embryo (Ginhoux and Jung, 2014). On the other hand, splenic MΦ and 
Kupffer cells showed a detectable HSC contribution in the steady state and particularly after 
interferon stimulation. These results further suggest that tissue MΦ represent a spectrum 
showing different degrees of self-renewal versus hematopoietic contribution (Gentek et al., 
2014). Second, we found that type I interferon, a known inducer of HSC proliferation 
(Essers et al., 2009; Walter et al., 2015), accelerated multilineage HSC differentiation. 
Moreover, it caused a nearly-complete equilibration of labeling in HSCs and mature cells, 
revealing that the few fully quiescent HSCs have been induced to differentiate. These data 
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suggest that cytokine-induced HSC proliferation can be directly coupled to increased 
differentiation without affecting its lineage pattern.
In conclusion, our results suggest that HSCs represent the major source of endogenous 
hematopoiesis, even though downstream progenitors may show homeostatic capacities and 
independent contributions. Our data are consistent with the recent clonal analysis in humans 
following hematopoietic reconsititution, revealing a major sustained contribution of 
multipotent HSCs over many years (Biasco et al., 2016). They also help explain the essential 
biology of HSCs, such as their active role in the aging of hematopoietic system (Adams et 
al., 2015) and the frequent origin of leukemogenic mutations in the HSC pool (Elias et al., 
2014). The genetic platform described herein should facilitate further studies of HSC 
differentiation in the steady state, during immune responses and in pathological conditions.
Experimental Procedures
Animals—The generation of BAC transgenic mouse strains is described in the 
Supplemental Experimental Procedures. Transgenic Pdzk1ip1-CreER animals were crossed 
to Cre-inducible reporter strain R26Tom/Tom (Madisen et al., 2010) and backcrossed to 
achieve homozygosity for the reporter allele. For label retention studies, Pdzk1ip1-CreER 
R26Tom/Tom mice were crossed with the R26rtTA/rtTA Col1a1tetO-H2BGFP/tetO-H2BGFP mice 
(Foudi et al., 2009) to generate Pdzk1ip1-CreER R26Tom/+ R26rtTA/+ Col1a1tetO-H2BGFP/+ 
F1 mice. Adult 8–10 week old mice were used in all experiments.
Animal procedures—All experiments with mice were performed according to protocols 
approved for use by the investigators (B.R. and C.J.E.) by their corresponding Institutional 
Animal Care and Use Committees. For cell proliferation analysis, adult Pdzk1ip1-GFP mice 
were injected i.p. with 1 mg BrdU (Sigma-Aldrich) and kept on water containing 0.8 mg/ml 
BrdU for 3 days. To induce recombination in the Pdzk1ip1-CreER R26Tom/Tom mice, a 
single dose of 50 mg/kg tamoxifen (Sigma-Aldrich) in sunflower oil was administered to 8–
10 week-old mice by gavage. To induce an interferon response, Pdzk1ip1-CreER 
R26Tom/Tom mice were treated with tamoxifen and then injected i.p. with 0.15 mg of 
polyinosinic:polycytidylic acid (poly-I:C, GE Life Sciences) 6, 8 and 10 days later. For label 
retention analyses, Pdzk1ip1-CreER R26Tom/+ R26rtTA/+ Col1a1tetO-H2BGFP/+ F1 mice were 
given doxycycline (2 mg/ml in drinking water containing 10 mg/ml sucrose) for 6 weeks to 
induce H2B-GFP expression. The mice were then kept without doxycycline for 14 weeks, 
treated with tamoxifen and analyzed 3 days later.
Peripheral blood (~0.1 ml) was collected by submandibular vein puncture with a sterile 
disposable lancet. BM biopsy was done as described (Verlinden et al., 1998) on isoflurane-
anesthetized animals by inserting a 28½ G insulin syringe needle into the joint surface of the 
femur through the patellar tendon and then into the bone cavity. Up to 20 μl of the bone 
marrow suspension (~106 cells) was collected.
Hematopoietic reconstitution—Sorted HSCs from Tg(Pdzk1ip1-GFP) animals (pure 
C57BL/6 background) were injected i.v. into lethally irradiated C57BL/6 recipients 
(B6.SJL) congenic for the CD45.1 isoform of pan-hematopoietic marker CD45. Total BM 
(105 cells) from B6.SJL mice were injected in parallel to ensure recipient survival. The 
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transplantation of ESLAM cells was done essentially as described (Dykstra et al., 2007; 
Kent et al., 2009). Briefly, sorted GFP+ and GFP− ESLAM HSCs were injected i.v. into 
sublethally irradiated B6.SJL-W41/W41 mice, which permit BM engraftment in the absence 
of lethal irradiation or the “rescue” BM. Donor-derived leukocytes in the blood and BM of 
recipient mice were defined as CD45.2+ CD45.1−.
Cell isolation and analysis—Cells from the peripheral blood and BM were subjected to 
red blood cell lysis and washed in PBS. Single-cell suspensions were stained for multicolor 
analysis with the indicated fluorochrome-conjugated antibodies (listed in the Supplemental 
Experimental Procedures, BD Biosciences or eBioscience). For BrdU incorporation, cells 
were stained for surface markers, fixed, permeabilized, and stained with an allophycocyanin-
conjugated anti-BrdU antibody according to the manufacturer’s protocol (APC BrdU Flow 
Kit, BD Biosciences). The samples were acquired using LSR II or Fortessa flow cytometers 
or sorted on an Influx flow sorter (BD Biosciences) equipped with 561 nm lasers for the 
detection of red fluorescent proteins. The data were analyzed using FlowJo software 
(TreeStar). Gene expression analysis by RNA-Seq and the staining of bone sections are 
described in Supplemental Experimental Procedures.
Statistics—Unless indicated otherwise, normal distribution was not assumed and 
significance was estimated by non-parametric Wilcoxon matched-pairs signed-rank test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• a subset of self-renewing HSC in the adult bone marrow was 
genetically marked
• HSC provide a major sustained contribution to endogenous 
hematopoiesis
• HSC give rise to all immune cell types except B-1a cells and tissue 
macrophages
• Multilineage contribution of HSC is accelerated by interferon response
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Fig. 1. Pdzk1ip1-GFP is expressed in a fraction of adult bone marrow HSCs
A. The expression of GFP within the total BM cells of adult Pdzk1ip1-GFP mice and the 
phenotype of gated GFP+ cells. The phenotypes of total or Lin− cells from control non-
transgenic BM are shown for comparison. Note that GFP+ Lin+ cells correspond to SSChi 
granulocytes and GFP+ Lin− cells correspond to HSCs.
B. Representative histograms of GFP expression in HSCs (LSK CD48− CD150+), MPPs 
(LSK CD48+ CD150−), MyPs (Lin− Sca1− cKit+ CD150−), and MEPs (Lin− Sca1− cKit+ 
CD150+) from Pdzk1ip1-GFP and control non-transgenic animals.
C. The fraction of GFP+ cells within the indicated BM populations (MkP defined as Lin− 
Sca1− cKit+ CD150+ CD41+; B, B220+; T, TCRβ+; Gran, Gr1+ CD11b+ SSChi). Bars 
represent medians of individual animals shown (n=13 for all cells except lymphocytes, for 
which n=5).
D. The expression of GFP in the HSC and progenitor (MPP1–4) populations defined 
according to (Cabezas-Wallscheid et al., 2014; Wilson et al., 2008) and the fraction of GFP+ 
cells within each population (bars represent medians of individual animals shown, n=7).
E. The expression of GFP in the HSC (HSC-1 and HSC-2) and progenitor (MPP and 
HPC-1) populations defined according to (Oguro et al., 2013). The expression of CD229 in 
the HPC-1 population is shown as a control (orange shadow histogram). Bars represent 
medians of individual animals shown (n=8).
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F. Expression of surface markers in GFP+ and GFP− HSCs. Control populations showing the 
expression range of each marker are shown as grey shadow histograms. Representative of 3 
individual animals.
G. The fraction of GFP+ and GFP− HSCs and progenitors (MPPs and MyPs) that 
incorporated BrdU after a 3-day pulse. Shown are values from 6 individual animals. 
Statistical significance: *p ≤ 0.05; **p ≤ 0.01.
See also Fig. S1.
Sawai et al. Page 18
Immunity. Author manuscript; available in PMC 2017 September 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. Pdzk1ip1-GFP+ HSCs have an undifferentiated expression profile and serial 
reconstitution capacity
A–B. RNA-Seq analysis of GFP+ and GFP− HSCs and MPPs from Pdzk1ip1-GFP mice. A. 
Unsupervised clustering dendrogram of the three samples.
B. Comparison with RNA-Seq profiles of wild-type HSCs and their immediate progeny 
(MPP1) (Cabezas-Wallscheid et al., 2014). Shown is pairwise comparison of transcript 
frequencies in HSCs and MPP1 for all genes (total) or for genes enriched in the GFP+ or 
GFP− HSCs from Pdzk1ip1-GFP mice (Dataset S1). Genes increased >2-fold in HSCs or 
MPP1 are highlighted in green or red, respectively.
C. The fraction of GFP+ cells in donor-derived HSCs and MPPs of primary recipients 
reconstituted with either GFP+ or GFP− HSCs six months post-transplant (mean ± S.D. of 5 
recipients).
D. The design of experiment to assess the ability of 20 sorted GFP+ (green) or GFP− (grey) 
CD45+ EPCR+ CD150+ CD48− (ESLAM) HSCs to reconstitute hematopoiesis in the 
primary (1°) and secondary (2°) recipients.
E. The fraction of donor-derived cells among different blood cell lineages in recipients 
assessed at least 16 weeks post-transplant in primary and secondary recipients of 20 ESLAM 
HSCs. Shown are values for individual recipient mice pooled from two independent 
experiments.
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See also Fig. S2 and Dataset S1.
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Fig. 3. Pdzk1ip1-CreER transgene inducibly labels undifferentiated HSCs
A. The expression of tdTomato (Tom) in Pdzk1ip1-CreER R26Tom/Tom mice or Cre-negative 
R26Tom/Tom controls three days after a single tamoxifen administration. Shown is 
representative expression of Tom within the total BM cells and the phenotype of gated Tom+ 
cells.
B,C. Representative histograms of Tom expression in the indicated cell populations (panel 
B) and the fraction of Tom+ cells within each population defined as in Fig. 1B,C (panel C, 
bars indicate median of individual animals, n=6).
D–E. Histograms and fractions of Tom expression in HSC/progenitor populations defined as 
in Fig. 1D and E, respectively (bars represent medians of individual animals shown, n=6).
F. Expression of surface markers in the Tom+ and Tom− subsets of HSCs. Indicated control 
populations showing the expression range of each marker are shown as grey shadow 
histograms. Representative of 3 individual animals.
G. The retention of H2B-GFP marker protein in the HSC/progenitor subsets. Pdzk1ip1-
CreER R26Tom R26rtTA Col1a1tetO-H2BGFP mice were pulsed for 6 weeks to express H2B-
GFP, chased for 14 weeks, induced with tamoxifen and analyzed 3 days later. Shown are 
representative histograms of H2B-GFP expression in Tom+ (+) or Tom− (−) HSCs, MPPs 
and MyPs, and the fractions of GFP+ cells in these populations from individual animals.
H. Labeled HSCs in the BM sections of Pdzk1ip1-CreER R26Tom/Tom mice 3 days post-
tamoxifen were detected by endogenous tdTomato fluorescence (arrowhead). Shown is 
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representative localization of Tom+ HSCs in sections stained for the sinusoid endothelial 
marker endomucin. Statistical significance: *p ≤ 0.05; **p ≤ 0.01; ns, not significant.
See also Fig. S3.
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Fig. 4. Labeled HSCs give rise to other cells within the HSC population
A. The fraction of labeled Tom+ cells in the HSC/progenitor compartment of Pdzk1ip1-
CreER R26Tom/Tom reporter mice. The HSC and progenitor subsets within the LSK 
population were defined on the basis of CD150/CD48 expression as shown in Fig. S4A. 
Shown are the median (bars) and individual values (circles) for animals sacrificed at 3 days, 
3–4 weeks or 11 weeks after tamoxifen treatment.
B. Continuous analysis of Tom+ cells in the HSC/progenitor compartment of tamoxifen-
treated reporter mice by serial BM biopsy. Shown is the fraction of Tom+ cells in HSC/
progenitor subsets in the same animals over time (median ± interquartile range, n= 5).
C. The dynamics of Tom+ label accumulation in the HSC compartment (left) and its 
decomposition into two-subset model (right). The modeled composition of the HSC 
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compartment is shown as a pie diagram. The labeled fraction of “top-level” HSCs is 
assumed to be constant since they are fully self-renewing while the labeled fraction of their 
progeny is steadily growing.
See also Fig. S4.
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Fig. 5. Labeled HSCs provide a major contribution to all lineage-committed progenitors
A–B. The fraction of labeled Tom+ cells in lineage-committed progenitors from Pdzk1ip1-
CreER R26Tom/Tom reporter mice. Cell populations in the BM and thymus were defined as 
shown in Fig. S5A. Shown are the median (bars) and values from individual animals 
(circles) at the indicated time points after tamoxifen treatment in the BM (panel A) and 
thymus (panel B). The median fractions of Tom+ HSCs at the respective time points are 
indicated by dashed lines.
C. The fraction of labeled Tom+ cells in myeloid progenitors and granulocytes (Grans) from 
Pdzk1ip1-CreER R26Tom/Tom reporter mice analyzed by serial BM biopsy. Shown is the 
fraction of Tom+ cells in the same animals over time (median ± interquartile range, n= 5).
D. A linear model of granulopoiesis based on serial BM biopsy data. Estimated values of 
differentiation and regeneration for each population are shown in the units of cells per week. 
Each population is shown by a circle with an area proportional to the number of cells, the 
width of each differentiation arrow (linear, blue) is proportional to the differentiation rate, 
the width of the regeneration arrow (circular, purple) is proportional to the regeneration rate, 
except the rates for MyPs that are ~100 times fold higher that for other populations.
See also Fig. S5.
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Fig. 6. Labeled HSCs provide a major contribution to mature hematopoietic cells
A. The fraction of labeled Tom+ cells in peripheral blood cells of Pdzk1ip1-CreER 
R26Tom/Tom reporter mice at the indicated time points after tamoxifen administration. 
(median ± range of 4 animals, representative of two experiments).
B–D. The fraction of labeled Tom+ cells in mature cell types of reporter mice. Shown are the 
median (bars) and values from individual animals (circles) at the indicated time points after 
tamoxifen treatment.
B. Major immune cell types in the spleen or thymus. The median fractions of Tom+ HSCs at 
the respective time points are indicated by dashed lines.
C. Conventional B cells in the spleen or peritoneal cavity (PC) and B-1a cells in PC.
D. Resident macrophages from the indicated tissues.
See also Fig. S6.
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Fig. 7. Interferon response accelerates HSC differentiation
Pdzk1ip1-CreER R26Tom/Tom reporter mice were induced with tamoxifen and then treated 
with poly-I:C on days 6, 8 and 10.
A. The fraction of Tom+ cells in the peripheral blood (presented as in Fig. 6A; median ± 
range of 4 animals).
B–D. The fraction of Tom+ cells at the 40 week endpoint; shown are the median (bars) and 
values from individual animals (circles).
B. Major immune cell types in the spleen or thymus. The median fraction of Tom+ HSCs at 
this time point is indicated for comparison (dashed line).
C. Conventional B cells in the spleen or PC and B-1a cells in PC.
D. Resident macrophages from the indicated tissues.
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